BeStock  
Stocks › Biotechnology › TVTX

Travere Therapeutic TVTX

US equityMarket cap rank #2128Biotechnology
$47.00 −$1.30 (-2.69%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $47.29 +0.62%
Open$48.09
Prev close$48.30
Day range$46.90 – $49.35
Volume1.33M
Market cap$4.51B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±5.1%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+18.6%
Worst reaction-11.8%

Stock move on the day after each report

-6.2%2023/Q4+3.1%2024/Q1-2.6%2024/Q2-1.4%2024/Q3-6.8%2024/Q4+1.9%2025/Q1-1.9%2025/Q2+18.6%2025/Q3+3.7%2025/Q4-0.2%2026/Q1+12.0%2026/Q2+0.3%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q32 Nov 2026After Market±9.7%+0.30%Within range
2026/Q24 Aug 2026After Market±13.3%+12.03%Within range
2026/Q14 May 2026After Market±6.2%-0.24%Within range
2025/Q419 Feb 2026After Market±18.0%+3.72%Within range
2025/Q330 Oct 2025After Market±10.3%+18.58%Bigger than priced
2025/Q26 Aug 2025After Market±20.9%-1.91%Within range
2025/Q11 May 2025After Market±15.2%+1.88%Within range
2024/Q420 Feb 2025After Market±17.1%-6.79%Within range
2024/Q331 Oct 2024Pre Market±18.5%-1.44%Within range
2024/Q21 Aug 2024After Market±19.0%-2.60%Within range
2024/Q16 May 2024After Market±28.9%+3.05%Within range
2023/Q415 Feb 2024After Market±34.7%-6.18%Within range
2023/Q37 Nov 2023After Market±23.2%-11.84%Within range
2023/Q23 Aug 2023After Market±14.8%-4.67%Within range
2023/Q14 May 2023After Market±17.4%+5.20%Within range
2022/Q423 Feb 2023After Market±11.8%+1.92%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q3

By business line

  • FILSPARI$200.19M 89.1%
  • Tiopronin products$20.00M 8.9%
  • License and collaboration revenue$4.37M 1.9%

Latest reported quarter: Q3, ended Sep 2026

Revenue$224.56M+36.2% YoY
Operating profit$45.01M+80.5% YoY
Net profit-$52.34M-303.6% YoY
Diluted EPS-$0.55-296.4% YoY
Free cash flow-$43.66M-3,847.6% YoY
Operating cash flow$98.20M

Revenue, last 8 quarters

$74.8MDec '24$81.7MMar '25$114.4MJun '25$164.9MSep '25$129.7MDec '25$127.2MMar '26$169.6MJun '26$224.6MSep '26

Net profit, last 8 quarters

$-60.3MDec '24$-41.2MMar '25$-12.8MJun '25$25.7MSep '25$2.7MDec '25$-37.1MMar '26$-34.8MJun '26$-52.3MSep '26

Profitability & balance sheet

Gross margin98.8%
Operating margin-3.1%
Net margin-18.7%
Return on equity-252.7%
Return on assets-17.5%
Return on invested capital-23.9%
Current ratio3.00
Liabilities / assets97.3%
Cash & investments$471.82M
Total debt$609.84M
Net cash (debt)-$138.03M

Discussion

No comments yet — be the first to weigh in on TVTX.

Sign in to join the discussion.

Scroll to Top